Constrained Peptidomimetics Reveal Detailed Geometric Requirements of Covalent Prolyl Oligopeptidase Inhibitors
Citations Over TimeTop 22% of 2009 papers
Abstract
Prolyl oligopeptidases cleave peptides on the carboxy side of internal proline residues and their inhibition has potential in the treatment of human brain disorders. Using our docking program fitted, we have designed a series of constrained covalent inhibitors, built from a series of bicyclic scaffolds, to study the optimal shape required for these small molecules. These structures bear nitrile functional groups that we predicted to covalently bind to the catalytic serine of the enzyme. Synthesis and biological assays using human brain-derived astrocytic cells and endothelial cells and human fibroblasts revealed that these compounds act as selective inhibitors of prolyl oligopeptidase activity compared to prolyl-dipeptidyl-aminopeptidase activity, are able to penetrate the cells and inhibit intracellular activities in intact living cells. This integrated computational and experimental study shed light on the binding mode of inhibitors in the enzyme active site and will guide the design of future drug-like molecules.
Related Papers
- → The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis(2015)196 cited
- → Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries(2011)72 cited
- → Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson’s disease: historical overview and future prospects(2016)14 cited
- → Crystal Structure Analysis of Human Dipeptidyl Peptidase IV (DPPIV)(2005)1 cited
- → CD26/dipeptidyl peptidase IV (DPPIV, DAPIV) is a useful molecular marker for thyroid carcinomas(2013)